Lrig2-Deficient Mice Are Protected against PDGFB-Induced Glioma

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Rondahl, Veronica ^a,c   Holmlund, Camilla ^a   Karlsson, Terese ^a   Wang, Baofeng ^a   Faraz, Mahmood ^a   Henriksson, Roger ^a,b   Hedman, Håkan ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN PROTEIN 1; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN LIKE DOMAIN PROTEIN 2; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN FOS; PROTEIN KINASE B; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GRADING; CANCER SUSCEPTIBILITY; CELL STRAIN HEK293; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EXON; FEMALE; FIBROBLAST; FOS GENE; GENOTYPE; GLIOBLASTOMA; GLIOMA; GROWTH RATE; HETEROZYGOTE; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; INTRACELLULAR SIGNALING; MALE; MORTALITY; MOUSE; NONHUMAN; OLIGODENDROGLIOMA; PDGFR BETA GENE; TRANSGENIC MOUSE; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; CARCINOGENESIS; CELL LINE; DISEASE SUSCEPTIBILITY; EXONS; FEMALE; GENES, IMMEDIATE-EARLY; GLIOMA; HETEROZYGOTE; HUMANS; INTRACELLULAR SPACE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; PLATELET-DERIVED GROWTH FACTOR; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SEQUENCE DELETION; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTIONAL ACTIVATION;

EID: 84883381112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073635     Document Type: Article

References (40)

1. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK, (2007) WHO classification of tumours of the central nervous system. 4th ed. Lyon, France: International Agency for Research on Cancer. 309pp.
2. Cairncross G, Jenkins R, (2008) Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 14: 352-357. doi:10.1097/PPO.0b013e31818d8178. PubMed: 19060598.
3. Di Rocco F, Carroll RS, Zhang J, Black PM, (1998) Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery 42: 341-346. doi:10.1097/00006123-199802000-00080. PubMed: 9482185.
4. Uhrbom L, Hesselager G, Nistér M, Westermark B, (1998) Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 58: 5275-5279. PubMed: 9850047.
5. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, et al. (2001) PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913-1925. doi:10.1101/gad.903001. PubMed: 11485986.
6. Suzuki Y, Sato N, Tohyama M, Wanaka A, Takagi T, (1996) cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains. J Biol Chem 271: 22522-22527. doi:10.1074/jbc.271.37.22522. PubMed: 8798419.
7. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, et al. (2001) Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 284: 1155-1161. doi:10.1006/bbrc.2001.5092. PubMed: 11414704.
8. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, et al. (2004) Characterization and tissue-specific expression of human LRIG2. Gene 332: 35-43. doi:10.1016/j.gene.2004.02.002. PubMed: 15145052.
9. Guo D, Holmlund C, Henriksson R, Hedman H, (2004) The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 84: 157-165. doi:10.1016/j.ygeno.2004.01.013. PubMed: 15203213.
10. Gur G, Rubin C, Katz M, Amit I, Citri A, et al. (2004) LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281. doi:10.1038/sj.emboj.7600342. PubMed: 15282549.
11. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, et al. (2004) The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056. doi:10.1074/jbc.M409703200. PubMed: 15345710.
12. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, et al. (2007) LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27: 1934-1946. doi:10.1128/MCB.00757-06. PubMed: 17178829.
13. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G, (2008) Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 28: 39-49. doi:10.1523/JNEUROSCI.2196-07.2008. PubMed: 18171921.
14. Hedman H, Nilsson J, Guo D, Henriksson R, (2002) Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 41: 352-354. doi:10.1080/028418602760169398. PubMed: 12234026.
15. Hedman H, Henriksson R, (2007) LRIG inhibitors of growth factor signalling- double-edged swords in human cancer? Eur J Cancer 43: 676-682. doi:10.1016/j.ejca.2006.10.021. PubMed: 17239582.
16. Tanemura A, Nagasawa T, Inui S, Itami S, (2005) LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430. PubMed: 15871317.
17. Lindström AK, Ekman K, Stendahl U, Tot T, Henriksson R, et al. (2008) LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18: 312-317. doi:10.1111/j.1525-1438.2007.01021.x. PubMed: 17624990.
18. Rouam S, Moreau T, Broët P, (2010) Identifying common prognostic factors in genomic cancer studies: a novel index for censored outcomes. BMC Bioinformatics 11: 150. doi:10.1186/1471-2105-11-150. PubMed: 20334636.
19. Krig SR, Frietze S, Simion C, Miller JK, Fry WH, et al. (2011) Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERα-positive breast cancer. Mol Cancer Res 9: 1406-1417. doi:10.1158/1541-7786.MCR-11-0227. PubMed: 21821674.
20. Muller S, Lindquist D, Kanter L, Flores-Staino C, Henriksson R, et al. (2013) Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. Int J Oncol 42: 247-252. PubMed: 23165628.
21. Wong VW, Stange DE, Page ME, Buczacki S, Wabik A, et al. (2012) Lrig1 controls intestinal stem-cell homeostasis by negative regulation of ErbB signalling. Nat Cell Biol 14: 401-408. doi:10.1038/ncb2464. PubMed: 22388892.
22. Powell AE, Wang Y, Li Y, Poulin EJ, Means AL, et al. (2012) The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149: 146-158. doi:10.1016/j.cell.2012.02.042. PubMed: 22464327.
23. Jensen KB, Watt FM, (2006) Single-cell expression profiling of human epidermal stem and transit-amplifying cells: Lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci U S A 103: 11958-11963. doi:10.1073/pnas.0601886103. PubMed: 16877544.
24. Jensen KB, Collins CA, Nascimento E, Tan DW, Frye M, et al. (2009) Lrig1 expression defines a distinct multipotent stem cell population in mammalian epidermis. Cell Stem Cell 4: 427-439. doi:10.1016/j.stem.2009.04.014. PubMed: 19427292.
25. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, et al. (2002) Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 521: 67-71. doi:10.1016/S0014-5793(02)02824-7. PubMed: 12067728.
26. Karlsson T, Mark EB, Henriksson R, Hedman H, (2008) Redistribution of LRIG proteins in psoriasis. J Invest Dermatol 128: 1192-1195. doi:10.1038/sj.jid.5701175. PubMed: 18037903.
27. Gumienny TL, Macneil L, Zimmerman CM, Wang H, Chin L, et al. (2010) Caenorhabditis elegans SMA-10/LRIG is a conserved transmembrane protein that enhances bone morphogenetic protein signaling. PLOS Genet 20: 6(5):e1000963. PubMed: 20502686.
28. Zhao H, Tanegashima K, Ro H, Dawid IB, (2008) Lrig3 regulates neural crest formation in Xenopus by modulating Fgf and Wnt signaling pathways. Development 135: 1283-1293. doi:10.1242/dev.015073. PubMed: 18287203.
29. Abraira VE, Del Rio T, Tucker AF, Slonimsky J, Keirnes HL, et al. (2008) Cross-repressive interactions between Lrig3 and netrin 1 shape the architecture of the inner ear. Development 135: 4091-4099. doi:10.1242/dev.029330. PubMed: 19004851.
30. Stuart HM, Roberts NA, Burgu B, Daly SB, Urquhart JE, et al. (2013) LRIG2 Mutations Cause Urofacial Syndrome. Am J Hum Genet 92: 259-264. doi:10.1016/j.ajhg.2012.12.002. PubMed: 23313374.
31. Holmlund C, Haapasalo H, Yi W, Raheem O, Brännström T, et al. (2009) Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology 29: 242-247. doi:10.1111/j.1440-1789.2008.00970.x. PubMed: 18992012.
32. Hedman H, Lindström AK, Tot T, Stendahl U, Henriksson R, et al. (2010) LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol 49: 812-815. doi:10.3109/0284186X.2010.492789. PubMed: 20553099.
33. Nilsson J, Starefeldt A, Henriksson R, Hedman H, (2003) LRIG1 protein in human cells and tissues. Cell Tissue Res 312: 65-71. PubMed: 12684867.
34. Holland EC, Hively WP, DePinho RA, Varmus HE, (1998) A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12: 3675-3685. doi:10.1101/gad.12.23.3675. PubMed: 9851974.
35. Tchougounova E, Kastemar M, Bråsäter D, Holland EC, Westermark B, et al. (2007) Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma. Oncogene 26: 6289-6296. doi:10.1038/sj.onc.1210455. PubMed: 17438529.
36. Schneider L, Clement CA, Teilmann SC, Pazour GJ, Hoffmann EK, et al. (2005) PDGFRalphaalpha signaling is regulated through the primary cilium in fibroblasts. Curr Biol 15: 1861-1866. doi:10.1016/j.cub.2005.09.012. PubMed: 16243034.
37. Reed DR, Lawler MP, Tordoff MG, (2008) Reduced body weight is a common effect of gene knockout in mice. BMC Genet 9: 4. doi:10.1186/1471-2156-9-4. PubMed: 18182103.
38. Zhang Y, Lu Y, Zhou H, Lee M, Liu Z, et al. (2008) Alterations in cell growth and signaling in ErbB3 binding protein-1 (Ebp1) deficient mice. BMC Cell Biol 9: 69. doi:10.1186/1471-2121-9-69. PubMed: 19094237.
39. Acampora D, Mazan S, Tuorto F, Avantaggiato V, Tremblay JJ, et al. (1998) Transient dwarfism and hypogonadism in mice lacking Otx1 reveal prepubescent stage-specific control of pituitary levels of GH, FSH and LH. Development 125: 1229-1239. PubMed: 9477321.
40. Shih AH, Dai C, Hu X, Rosenblum MK, Koutcher JA, et al. (2004) Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. Cancer Res 64: 4783-4789. doi:10.1158/0008-5472.CAN-03-3831. PubMed: 15256447.